Amphenol Total Cost of Revenue increased by 21.2% to $4.82B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 52.2%, from $3.17B to $4.82B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 18.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.81B | $1.93B | $2.09B | $2.03B | $2.13B | $2.24B | $2.20B | $2.03B | $2.06B | $2.15B | $2.23B | $2.17B | $2.40B | $2.68B | $2.84B | $3.17B | $3.60B | $3.84B | $3.98B | $4.82B |
| QoQ Change | — | +6.5% | +8.1% | -2.9% | +5.3% | +4.8% | -1.5% | -7.8% | +1.6% | +4.3% | +3.6% | -2.7% | +10.6% | +11.9% | +5.8% | +11.6% | +13.6% | +6.6% | +3.7% | +21.2% |
| YoY Change | — | — | — | — | +17.8% | +15.9% | +5.6% | +0.3% | -3.3% | -3.8% | +1.2% | +6.7% | +16.2% | +24.7% | +27.4% | +46.1% | +50.1% | +43.0% | +40.2% | +52.2% |